These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 23615975)

  • 1. Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.
    De Deurwaerdère P; Lagière M; Bosc M; Navailles S
    Exp Brain Res; 2013 Oct; 230(4):477-511. PubMed ID: 23615975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Subset of Purposeless Oral Movements Triggered by Dopaminergic Agonists Is Modulated by 5-HT
    Lagière M; Bosc M; Whitestone S; Benazzouz A; Chagraoui A; Millan MJ; De Deurwaerdère P
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin involvement in the basal ganglia pathophysiology: could the 5-HT2C receptor be a new target for therapeutic strategies?
    Di Giovanni G; Di Matteo V; Pierucci M; Benigno A; Esposito E
    Curr Med Chem; 2006; 13(25):3069-81. PubMed ID: 17073648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of 5-HT2C receptors in the enhancement of c-Fos expression induced by a 5-HT2B/2C inverse agonist and 5-HT 2 agonists in the rat basal ganglia.
    Navailles S; Lagière M; Le Moine C; De Deurwaerdère P
    Exp Brain Res; 2013 Oct; 230(4):525-35. PubMed ID: 23681297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonergic control of the glutamatergic neurons of the subthalamic nucleus.
    Ugedo L; De Deurwaerdère P
    Prog Brain Res; 2021; 261():423-462. PubMed ID: 33785138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulation of serotonin2C receptors elicits abnormal oral movements by acting on pathways other than the sensorimotor one in the rat basal ganglia.
    Beyeler A; Kadiri N; Navailles S; Boujema MB; Gonon F; Moine CL; Gross C; De Deurwaerdère P
    Neuroscience; 2010 Aug; 169(1):158-70. PubMed ID: 20447448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens.
    De Deurwaerdère P; Navailles S; Berg KA; Clarke WP; Spampinato U
    J Neurosci; 2004 Mar; 24(13):3235-41. PubMed ID: 15056702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.
    Di Matteo V; Pierucci M; Esposito E; Crescimanno G; Benigno A; Di Giovanni G
    Prog Brain Res; 2008; 172():423-63. PubMed ID: 18772045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders.
    Di Giovanni G; De Deurwaerdère P
    Pharmacol Ther; 2016 Jan; 157():125-62. PubMed ID: 26617215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease.
    Miguelez C; Morera-Herreras T; Torrecilla M; Ruiz-Ortega JA; Ugedo L
    Front Neural Circuits; 2014; 8():21. PubMed ID: 24672433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central serotonin2C receptor: from physiology to pathology.
    Di Giovanni G; Di Matteo V; Pierucci M; Benigno A; Esposito E
    Curr Top Med Chem; 2006; 6(18):1909-25. PubMed ID: 17017966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Nicholson SL; Brotchie JM
    Eur J Neurol; 2002 Nov; 9 Suppl 3():1-6. PubMed ID: 12464115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia.
    Haleem DJ
    Behav Pharmacol; 2015 Feb; 26(1-2):45-58. PubMed ID: 25503261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.
    Alex KD; Pehek EA
    Pharmacol Ther; 2007 Feb; 113(2):296-320. PubMed ID: 17049611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin2C receptors and drug addiction: focus on cocaine.
    Devroye C; Filip M; Przegaliński E; McCreary AC; Spampinato U
    Exp Brain Res; 2013 Oct; 230(4):537-45. PubMed ID: 23748692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.
    Mehler-Wex C; Riederer P; Gerlach M
    Neurotox Res; 2006 Dec; 10(3-4):167-79. PubMed ID: 17197367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin2c receptor constitutive activity: in vivo direct and indirect evidence and functional significance.
    Navailles S; Lagière M; Guthrie M; De Deurwaerdère P
    Cent Nerv Syst Agents Med Chem; 2013 Jun; 13(2):98-107. PubMed ID: 23441866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of dopamine release by striatal 5-HT2C receptors.
    Alex KD; Yavanian GJ; McFarlane HG; Pluto CP; Pehek EA
    Synapse; 2005 Mar; 55(4):242-51. PubMed ID: 15668911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats.
    Eberle-Wang K; Mikeladze Z; Uryu K; Chesselet MF
    J Comp Neurol; 1997 Jul; 384(2):233-47. PubMed ID: 9215720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system.
    Di Matteo V; Di Giovanni G; Di Mascio M; Esposito E
    Neuropharmacology; 1999 Aug; 38(8):1195-205. PubMed ID: 10462132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.